IP Library › Granted Patent US 12,383,612
Granted Patent B2
US 12,383,612 · App. 17/721,115 · Granted Aug 12, 2025

Vaccine to protect a pig against

Inventors: Maarten Hendrik Witvliet (Oostrum, NL); Johanna Jacoba Elisabeth Bijlsma (Nijmegen, NL)
Assignee: Intervet Inc.
A61K39/102C07K14/285A61K2039/54A61K2039/552A61K2039/55544
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,612
App. No.
17/721,115
Granted
Aug 12, 2025
Kind
B2
Abstract

The present invention pertains to a vaccine to protect a pig against an infection with Actinobacillus pleuropneumoniae , the vaccine comprising an RTX toxin of Actinobacillus pleuropneumoniae recombinantly expressed by a baculovirus, and a pharmaceutically acceptable carrier.

Claims (6)

1. A method of protecting a pig against an infection with Actinobacillus pleuropneumoniae by administering to the pig a dose of a vaccine, wherein the vaccine comprises an isolated and purified 110 kDa ApxI toxin of Actinobacillus pleuropneumoniae expressed recombinantly by a baculovirus, wherein the vaccine is without LPS or another hetero-toxin, and wherein the vaccine further comprises an adjuvant.

2. The method of claim 1 , wherein the vaccine is administered systemically.

3. The method of claim 1 , wherein the vaccine is administered intramuscularly.

4. The method of claim 1 , wherein the vaccine is administered intradermally.

5. The method of claim 1 , wherein the vaccine further comprises a pharmaceutically acceptable carrier.

6. The method of claim 1 , wherein the adjuvant is a mineral oil-containing adjuvant.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2022
From: WITVLIET, MAARTEN HENDRIK; BIJLSMA, JOHANNA JACOBA ELISABETH
To: INTERVET INC.
Reel/Frame 059604/0661 →
Priority Claims (1)
EP 17209021 · Dec 20, 2017 · regional
Continuity (2)
Division 16954055
Related Publication 20220233675A1 · Jul 28, 2022
References Cited (27)
US 20040202678A1 · Segers · 2004 [cited by applicant]
US 20170340723A1 · Witvliet et al. · 2017 [cited by applicant]
CN 102481350A · 2012 [cited by applicant]
EP 0595188A2 · 1994 [cited by applicant]
EP 0810283A2 · 1997 [cited by applicant]
JP 6135853A · 1994 [cited by applicant]
WO 9716532A1 · 1997 [cited by applicant]
WO 2011015614A1 · 2011 [cited by applicant]
WO 2016093157A1 · 2016 [cited by applicant]
Macjine Translation of WO 2016093157 A 1, pp. 1-8, 2016. [cited by examiner]
Zheng et al. J. Biol. Chem. 285: 349-356, 2010. [cited by examiner]
Sadilkova et al. Vet. Res. 43: 1-12, 2012. [cited by examiner]
Ahrens, U. et al., Efficacy of the classical swine fever (CSF) marker vaccine Porcilis Pesti in pregnant sows, Veterinary Microbiology, 2000, pp. 83-97, vol. 77, No. 1-2. [cited by applicant]
Amar Safdar et al., Baculovirus-expressed influenza vaccine: a novel technology for safe and expeditious vaccine production for human use, Expert opinion on investigational drugs, Jul. 1, 2007, pp. 927-934, vol. 16, No.… [cited by applicant]
European Search Report for 17209021.9 dated Jun. 6, 2018, 13 pages. [cited by applicant]
Felberbaum, Rachael S., The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors, Biotechnology Journal, 2015, 702-714, 10. [cited by applicant]
Gomes, Amitha Reena et al., An Overview of Heterologous Expression Host Systems for the Production of Recombinant Proteins, Advances in Animal and Veterinary Sciences, 2016, 346-356, 4(7). [cited by applicant]
International Search Report for application PCTEP201808575 mailed on Mar. 25, 2019, 5 sheets. [cited by applicant]
Kim, Jung-Mi et al., Surface-Displayed Expression of a Neutralizing Epitope of ApxlIA Exotoxin in [cited by applicant]
Lui, J., et al., In vivo induced RTX toxin ApxIVA is essential for the full virulence of Actinobacillus pleuropneumoniae, Veterinary Microbiology, 2009, pp. 282-289, vol. 137, No. 3-4. [cited by applicant]
Mahendrasingh Ramjeet, et al., Mutation in the LPS outer core biosynthesis gene, galU, affects LPS Interaction with the RTX toxins ApxI and ApxIl and cytolytic activity of Actinobacillus pleuropneumoniae serotype 1, Mol… [cited by applicant]
Seah, J.N. et al., The N-Terminal Domain of RTX Toxin ApxI of Actinobacillus pleuropneumoniae Elicits Protective Immunity in Mice, Infection and Immunity, 2002, 6464-6467, 70(11). [cited by applicant]
Shin, Min-Kyoung et al., Oral immunization of mice with [cited by applicant]
Shin, Sung Jae et al., Enhancement of protective immune responses by oral vaccination with [cited by applicant]
Shin, Sung Jae et al., Induction of antigen-specific immune responses by oral vaccination with [cited by applicant]
Van Den Bosch, Han et al., Interference of outer membrane protein PaIA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs, Vaccine, 2003, 3601-3607, 21. [cited by applicant]
Wang, C., et al., Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae, Vaccine, 2009, pp. 5816-5821, vol. 27, No. 42. [cited by applicant]